Company Overview

Medpace Holdings, Inc. is a global clinical contract research organization (CRO) that provides outsourced clinical development services to the pharmaceutical, biotechnology, and medical device industries. The company operates within the life sciences and healthcare services sectors, focusing primarily on supporting small- to mid-sized biotechnology firms in the development of drugs, biologics, and medical devices across multiple therapeutic areas.

Medpace’s core revenue is generated from providing end-to-end clinical trial services, including study design, regulatory strategy, clinical monitoring, data management, biostatistics, and medical writing. The company is known for its fully integrated service model, which differentiates it from many CRO peers that operate with more fragmented or outsourced service structures. Founded in 1992, Medpace evolved from a U.S.-based clinical services firm into a publicly traded global CRO following its initial public offering in 2016, with a strategic emphasis on organic growth rather than large-scale acquisitions.

Business Operations

Medpace operates as a single-reportable segment CRO but organizes its services around functional expertise and therapeutic specialization. Its operations support Phase I through Phase IV clinical trials, with particular strength in early- and mid-stage development. Revenue is primarily earned through long-term service contracts tied to clinical trial milestones and patient enrollment progress.

The company conducts both domestic and international operations, with clinical activities spanning North America, Europe, Asia-Pacific, and Latin America. Medpace maintains internal control over key technologies and capabilities, including centralized laboratories, bioanalytical services, and imaging, which are operated through wholly owned subsidiaries such as Medpace Reference Laboratories. The company does not rely heavily on joint ventures, instead favoring a vertically integrated operating model to maintain quality control and operational consistency.

Strategic Position & Investments

Medpace’s strategic direction centers on disciplined growth, operational efficiency, and deep therapeutic expertise. The company emphasizes organic expansion through increased client penetration, geographic reach, and therapeutic area specialization rather than pursuing large acquisitions. This strategy has been reinforced by consistent investment in internal infrastructure, technology platforms, and scientific personnel.

While Medpace has made selective investments to enhance capabilities—such as expanding laboratory services and global office locations—it has not engaged in transformative mergers or acquisitions in recent years. The company is actively involved in emerging areas of clinical research, including rare diseases, oncology, metabolic disorders, and central nervous system indications. Its integrated model and focus on mid-sized biotech sponsors position Medpace as a strategic partner for companies seeking full-service development support without managing multiple vendors.

Geographic Footprint

Medpace is headquartered in Cincinnati, Ohio, and maintains a broad international presence to support global clinical trials. The company operates offices and clinical sites across North America, Europe, Asia-Pacific, and Latin America, enabling patient recruitment and regulatory engagement in both established and emerging markets.

Its international footprint supports multinational trials and allows Medpace to serve clients targeting regulatory approvals in major jurisdictions, including the United States, the European Union, and parts of Asia. The company’s geographic diversification also helps mitigate regional regulatory and enrollment risks while strengthening its role as a global CRO partner.

Leadership & Governance

Medpace was founded by August J. Troendle, who has played a central role in shaping the company’s integrated operating model and long-term strategic vision. Leadership emphasizes scientific rigor, operational discipline, and maintaining internal control over clinical development processes.

Key members of the executive leadership team include:

• August J. Troendle – Chief Executive Officer and Chairman
• Jesse Geiger – Chief Financial Officer
• Michael J. Witte – President
• Bart Meers – Chief Operating Officer
• Brian Leamy – Chief Global Business Development Officer

The governance structure reflects a founder-led model with significant insider ownership, aligning executive decision-making with long-term shareholder value and operational performance.